Nabriva Therapeutics AG (NBRV) insider have most recently took part in a trading activity. On Nov 29, 2017 Lavino Francesco Maria, Chief Commercial Officer bought 1,569 shares having total worth of $9,869 at the price of $6.29 per share, following the transaction a total of 1,569 shares owned by Lavino Francesco Maria.
The stock has experienced a total of 2 insider trades in the past three months. These trades include 1 sell activities and 1 buy trades. Furthermore, over the past 12 months , the stock was traded 24 times by insiders. In 23 of these trades, the insider was a seller while an employee of the company was the buyer in 1 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Nabriva Therapeutics AG (NBRV) traded up 1.26% on Nov 30, 2017, hitting $6.42. 182,572 shares of the company’s stock traded hands. Nabriva Therapeutics AG has a 52 week low of $4 and a 52 week high of $12.62. The company’s market cap is $156 million.
Nabriva Therapeutics AG (NBRV) last announced its earnings results on Nov 9, 2017. The company reported -0.79 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.57 by $0.22. The company had revenue of $1 million for the quarter, compared to the consensus estimate of $1 million. During the same quarter in the previous year, the company posted -6.56 earnings per share.
|earnings per share||-0.79||-0.54||-5.60||-6.56||0.00||-0.39||-0.17|
Latest posts by William White (see all)
- Insider Trading Update: Immersion Corporation $IMMR - December 15, 2017
- Insider Trading in Focus: Depomed, Inc. $DEPO - December 15, 2017
- Notable Insider Trading: Safety, Income and Growth, Inc. $SAFE - December 15, 2017